Marizyme, Inc. (MRZM)

Market Cap	132.00 -100.0%
Revenue (ttm)	183.42K -69.0%
Net Income	-14.95M
EPS	-0.13
Shares Out	131.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Average Volume	22,337
Open	0.0000
Previous Close	0.0000
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.1195
Beta	1.04
RSI	41.82
Earnings Date	May 14, 2026

About Marizyme

Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery. Its product portfolio includes DuraGraft, a biocompatible intraoperative vascular graft storage and flushing solution; and Krillase, an enzyme that acts to break protein bonds and has applications in wo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: MRZM

Financial Performance

In 2023, Marizyme's revenue was $645,810, an increase of 176.60% compared to the previous year's $233,485. Losses were -$65.35 million, 71.2% more than in 2022.